Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Immunization, Passive
  • Tauopathies
  • Transcription Factors
  • tau Proteins

abstract

  • We have used an adeno-associated viral (AAV) vector to deliver the genes encoding an anti-phospho-tau monoclonal antibody, PHF1, directly to the brain of mice that develop neurodegeneration due to a tau mutation that causes frontotemporal dementia (FTD). When administered systemically, PHF1 has been shown to modestly reduce tau pathology and neurodegeneration. Since such antibodies do not readily cross the blood-brain barrier, we used an AAV vector to deliver antibody directly to the hippocampus and observed much higher antibody levels and a much greater reduction in tau pathology. Using AAV vectors to deliver antibodies like PHF1 directly to brain may constitute a novel approach to treating various neurodegenerative disorders, such as FTD and Alzheimer's disease.

publication date

  • December 7, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1523/JNEUROSCI.2016-16.2016

PubMed ID

  • 27927959

Additional Document Info

start page

  • 12425

end page

  • 12435

volume

  • 36

number

  • 49